Tirzepatide's results are only part of your decision.
The weight-loss findings matter. So do the parts of the decision a headline leaves out.
A strong result still needs context.
What the human comparison tells us
Tirzepatide acts on GIP and GLP-1, two gut-hormone signals. These play roles in appetite and blood-sugar control. We don't treat “two” as a score that settles which medicine fits someone.
The approved weight-management product Zepbound (tirzepatide) is for adults. Its label covers obesity, or overweight when another weight-related condition is present, alongside changes in diet and physical activity. An approved medicine still has eligibility limits. Sharing a goal with the trial participants doesn't establish that you qualify.
In a direct obesity trial comparing tirzepatide with semaglutide, average weight loss was greater with tirzepatide. The adults enrolled had obesity without type 2 diabetes. The study's funder was Lilly, which makes tirzepatide. Researchers and participants both knew which treatment was being used.
That is useful human evidence. It also leaves questions for an individual conversation: how relevant were those participants to you, what are the risks, and what follow-up would treatment involve?
The trial didn't include AOD-9604 or test tesamorelin's HIV-related abdominal-fat purpose. We can't use it to hand every peptide a place in a weight-loss league table.
Side effects belong beside the result
The Zepbound label lists nausea, diarrhoea, vomiting and constipation. Stomach side effects can be severe. Fluid loss can harm the kidneys, and warnings also cover pancreas and gallbladder problems.
The label makes other medicines, pregnancy plans and upcoming surgery relevant to a prescribing conversation. Those ordinary details can change the risks.
We'd want time to talk them through. A good average result doesn't make a difficult side effect any easier for the person having it.
Some medical histories rule it out
There's a boxed warning about thyroid tumours in rats. That's the FDA's strongest warning format. The risk to people remains unknown.
A rare thyroid cancer, medullary thyroid cancer, rules treatment out when you or a family member has had it. MEN 2 also rules it out; that's an inherited condition. A clinician needs that history; a trial average can't answer for it.
A prescription isn't the only sensible ending
You can take the evidence seriously and still decide against treatment with your clinician. The comparison separates the goals; the questions page handles common mix-ups.
For a compounded preparation, a shared ingredient brings no FDA approval.